Press Release Archive
09/28/2009
CSL Biotherapies reaches agreement with Merck & Co. on rights to market and distribute Afluria® in the U.S.
CSL Biotherapies and its parent company, CSL Limited (ASX: CSL), one of the world's leading manufacturers of influenza vaccine, have reached an agreement with Merck & Co., Inc. on rights to market and distribute Afluria® in the United States under an exclusive, six-year agreement effective September 3, 2009. Afluria, a CSL product, is a non-adjuvanted trivalent seasonal influenza vaccine sold in two different formulations: thimerosal-free, pre-filled syringes, and in multi-dose vials.
More.
08/18/2009
U.S. FDA Licenses CSL Biotherapies’ New U.S. Influenza Vaccine Filling and Packaging Facility in Illinois
CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has licensed the company’s newest vaccine filling and packaging facility, located in Kankakee, Ill. The facility, part of an investment to expand CSL’s U.S. influenza vaccine production capabilities, includes a high-speed, single-dose vaccine syringe filling line.
More.
07/27/2009
CSL Biotherapies Starts Shipment of Seasonal Influenza Vaccine for the 2009-2010 Flu Season
CSL Biotherapies, a subsidiary of one of the world's leading manufacturers of thimerosal-free seasonal influenza vaccine, announced today that it has begun shipment of its seasonal influenza virus vaccine to a national network of U.S. distributors for the 2009-2010 season. CSL Biotherapies plans to deliver more than eight million doses of the vaccine, the majority of which will be in single-dose, thimerosal-free, pre-filled syringes.
More.
07/09/2009
CDC, AWHONN and CSL Biotherapies Partner to Educate Healthcare Providers on the Impact of Novel H1N1 Pandemic on Influenza Management in Pregnant Women
To address public health concerns about the novel influenza A pandemic virus – H1N1 -- and the implications of it on the upcoming influenza (flu) season, the Association of Women’s Health, Obstetric and Neonatal Nurses (AWHONN) hosted a late-breaking educational session for healthcare providers who are on the front-lines of care for pregnant women at the AWHONN 2009 annual convention. Funded by CSL Biotherapies, “A Tale of Two Flus: A Focus on Seasonal and Novel H1N1 During Pregnancy” featured speakers from the Centers for Disease Control (CDC) and provided valuable insights and recommendations in the months leading up to the Fall flu season.
More.
03/23/2009
National Influenza Vaccine Summit Announces Recipients of the 2009 Immunization Excellence Award Winners
The National Influenza Vaccine Summit announces the recipients of the Annual National Influenza Vaccine Summit (NIVS) Immunization Excellence Awards:
Overall 2008-09 Season Activity: Sickness Prevention Achieved Through Regional Collaboration (SPARC), Lakeville, CT and Newton, MA;
Healthcare Personnel Campaign: Children’s Hospitals and Clinics of Minnesota, Saint Paul, MN;
18 years and younger Campaign: The Wellness Company, Providence, RI; Coalition Campaign: Maryland Partnership for Prevention, Owings Mills, MD; and
Corporate Campaign: MinuteClinic CVS/pharmacy, Minneapolis, MN, and National Women’s Health Resource Center, Red Bank, NJ.
More.
12/22/2008
CSL Biotherapies Announces Influenza Vaccine Pre-Booking Open for the 2009-2010 Flu Season
CSL Biotherapies, a subsidiary of one of the world’s leading manufacturers of influenza vaccine, today announced that healthcare providers now have the opportunity to pre-book the company’s influenza virus vaccine through either www.mercuryfreefluvaccine.com or the toll-free number,
1-888-435-8633. The majority of CSL Biotherapies’ vaccine supply for the 2009-2010 flu season will be offered as thimerosal-free, single-dose, pre-filled syringes. To help increase access to the thimerosal-free vaccine, CSL Biotherapies will offer value programs for a limited time to healthcare providers who pre-book through authorized distributors.
More.
11/14/2008
Jesse Palmer Throws a "Season Pass" at Influenza Awareness to College Students Nationwide
To increase flu vaccination rates among college students,
CSL Biotherapies is partnering on
Season Pass© with Jesse Palmer, ESPN co-host of "College Football Live" and former pro football player.
Season Pass is a novel program designed to immunize as many college students as possible during the 2008-2009 influenza (flu) season. College students are at risk for contracting the flu due to their close living quarters and frequent contact with other students.
Season Pass aims to educate college students about influenza prevention and motivate them to visit their on-campus health center to get vaccinated.
More.
05/13/2008
CSL Marks 40 Years in the Influenza Vaccine Market
CSL Limited today celebrated its 40th year as a leading manufacturer of influenza (flu) vaccine. The company’s vaccine, Fluvax
®, is a Thiomersal-free influenza vaccine that is approved for use in adults and children in Australia and New Zealand. This vaccine is known as Afluria™, Enzira™, Nilgrip™, and X-Flu™ in 17 different countries, including the US and European markets. Additionally, CSL supplies the antigen used to manufacture the flu vaccine in 24 countries.
More.
04/03/2008
CSL Biotherapies Announces Afluria® Pre-Booking Open
CSL Biotherapies announced today that healthcare providers now have the opportunity to pre-book Afluria® (influenza virus vaccine) through either
www.afluria.com or at the company’s toll-free number 1-888-435-8633. CSL Biotherapies, which entered the U.S. market last season, plans to produce approximately 6 million doses of Afluria for delivery in time for the upcoming season. The majority of the Afluria supply for the upcoming season will be in single-dose, thimerosal-free, pre-filled syringes.
More.